BRUKER CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.97 USD | +0.47% |
|
+4.13% | +10.19% |
| 04-26 | Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference | CI |
| 04-22 | Bruker Agrees Signs Asset Purchase Deal With NanoString Technologies | MT |
| Sales 2024 * | 3.26B 261B | Sales 2025 * | 3.48B 278B | Capitalization | 11.77B 942B |
|---|---|---|---|---|---|
| Net income 2024 * | 338M 27.06B | Net income 2025 * | 448M 35.86B | EV / Sales 2024 * | 3.75 x |
| Net Debt 2024 * | 484M 38.77B | Net Debt 2025 * | 428M 34.25B | EV / Sales 2025 * | 3.51 x |
| P/E ratio 2024 * |
34.2
x | P/E ratio 2025 * |
25.9
x | Employees | 9,707 |
| Yield 2024 * |
0.25% | Yield 2025 * |
0.25% | Free-Float | 55.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bruker Corporation
More recommendations
More press releases
| 1 day | +0.47% | ||
| 1 week | +4.13% | ||
| Current month | -13.81% | ||
| 1 month | -12.37% | ||
| 3 months | +12.51% | ||
| 6 months | +40.28% | ||
| Current year | +10.19% |
1 week
77.08
83.32
1 month
77.0894.52
Current year
68.6694.86
1 year
53.7994.86
3 years
48.4294.86
5 years
30.7894.86
10 years
15.7894.86
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Laukien
CEO | Chief Executive Officer | 64 | 31/01/91 |
Gerald Herman
DFI | Director of Finance/CFO | 66 | 30/11/16 |
Thorsten Thiel
IRO | Public Communications Contact | - | 30/09/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Ornell
BRD | Director/Board Member | 66 | 18/08/15 |
William Linton
BRD | Director/Board Member | 77 | 31/01/00 |
Robert Rosenthal
BRD | Director/Board Member | 67 | 10/11/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.16% | 96 M€ | -1.45% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 80.97 | +0.47% | 488,537 |
| 25/04/24 | 80.59 | -1.96% | 1,091,983 |
| 24/04/24 | 82.2 | -0.32% | 987,514 |
| 23/04/24 | 82.46 | +5.65% | 1,083,554 |
| 22/04/24 | 78.05 | +0.37% | 811,225 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions. The Companyâs BSI BioSpin segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. Its BSI Nano segment designs, manufactures and distributes advanced X-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments. Its Bruker Energy & Supercon Technologies (BEST) segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and big science research. It offers scanning transmission electron microscopes (STEM). It also offers advanced research Raman microscopy systems.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
80.97
USD
Average target price
89.4
USD
Spread / Average Target
+10.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.19% | 11.77B | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- BRKR Stock
